ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Pembrolizumab is on this study

  • The record lists it as a treatment.
  • Claude Opus 5.5 judged it given beside what the study tests. Nov 2, 2026, 3:40 AM UTC
  • The role rule says the same.
  • So Pembrolizumab's page lists this study under “Given beside what is tested”.
7 links0 made here, not in the record13 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT05081609A Study to InvestigateSafety and Tolerability ofTransCon IL-2 β/γ Alone orin Combination WithPembrolizumab and/orTransCon TLR7/8 Agonist orOther Anticancer TherapiesAscendis Pharma Oncology DivisPhase 1/Phase 2 · active not rRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 13 · ClinicalTrials.gov record · Version of 2026-10-13Version of 2026-10-13CONDITIONSNeoplasm MetastasisThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseAs of now · Rule based · Main conditionMain conditionUterine Cervical NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termDRUGSPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundINT007009Entry “Chemotherapy drug”, read by ou…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundINT010984Entry “TransCon TLR7/8 Agonist”, read…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerAdo-Trastuzumab EmtansineEntry “Trastuzumab emtansine (T-DM1)”…›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Oct 13 · changes seen, not judgments
Nov 2PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 2INT007009Claude Opus 5.5BackgroundCurrent
Nov 2INT010984Claude Opus 5.5BackgroundCurrent
Nov 2TrastuzumabClaude Opus 5.5Background · partnerCurrent
Nov 2Ado-Trastuzumab EmtansineClaude Opus 5.5Background · partnerCurrent
Nov 14Neoplasm MetastasisRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Uterine Cervical NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18INT007009Rule based · role ruleBackgroundAgrees
Nov 18INT010984Rule based · role ruleBackgroundAgrees
Nov 18TrastuzumabRule based · role ruleBackgroundAgrees
Nov 18Ado-Trastuzumab EmtansineRule based · role ruleBackgroundAgrees
As of nowNeoplasm MetastasisRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.